PF-07220060 CDK4 inhibitor

Phase 2

PF-07220060 CDK4 inhibitor is one of 2 therapeutic programs targeting Advanced or Metastatic Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced or Metastatic Breast CancerActive, not recruiting

Advanced or Metastatic Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Advanced or Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Faslodex

FFresenius Kabi USA, LLC

Phase 2

1 2

PF-07220060 CDK4 inhibitor

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Advanced or Metastatic Breast Cancer

NCT06105632

Clinical

Trials by Indication[1]

Advanced or Metastatic Breast Cancer1 trial

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT06105632·333 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PF-07220060 CDK4 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for PF-07220060 CDK4 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Pfizer

PF-07220060 CDK4 inhibitor

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Advanced or Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News